Autopsy report · NCT04101357
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
Cause of deathFunding or business
“Sponsor decision”
Life of this trial
- Registered 9 months before it started.
- Ran for about 3 years 11 months before it stopped.
- 54 participants enrolled.
- Results were posted on the registry 10 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- BioNTech SE
- Sponsor type
- Industry
- Conditions
- Solid Tumor; Extensive-stage Small Cell Lung Cancer
- Interventions
- BNT411; Atezolizumab; Carboplatin; Etoposide
- Participants
- 54
- Sites
- 12
- Countries
- Germany, Spain, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.